| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunotherapy, Adoptive | 15 | 2022 | 170 | 2.780 |
Why?
|
| Melanoma | 26 | 2017 | 459 | 2.090 |
Why?
|
| Receptors, Antigen, T-Cell | 18 | 2022 | 371 | 1.740 |
Why?
|
| Proto-Oncogene Proteins B-raf | 14 | 2017 | 138 | 1.660 |
Why?
|
| T-Lymphocytes | 20 | 2022 | 1195 | 1.540 |
Why?
|
| Dendritic Cells | 8 | 2014 | 425 | 1.190 |
Why?
|
| Cancer Vaccines | 7 | 2015 | 156 | 1.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 16 | 2022 | 558 | 1.020 |
Why?
|
| Genetic Therapy | 8 | 2023 | 342 | 0.920 |
Why?
|
| Sulfonamides | 11 | 2015 | 300 | 0.900 |
Why?
|
| Indoles | 11 | 2015 | 318 | 0.870 |
Why?
|
| Lentivirus | 9 | 2010 | 36 | 0.860 |
Why?
|
| Genetic Vectors | 11 | 2018 | 439 | 0.840 |
Why?
|
| Antigens, Neoplasm | 10 | 2022 | 325 | 0.780 |
Why?
|
| Melanoma, Experimental | 7 | 2019 | 103 | 0.650 |
Why?
|
| Neoplasms | 10 | 2022 | 2898 | 0.640 |
Why?
|
| Cell Line, Tumor | 28 | 2021 | 2426 | 0.630 |
Why?
|
| Skin Neoplasms | 8 | 2015 | 546 | 0.620 |
Why?
|
| Drug Resistance, Neoplasm | 9 | 2017 | 592 | 0.600 |
Why?
|
| Transduction, Genetic | 11 | 2018 | 153 | 0.580 |
Why?
|
| Protein Kinase Inhibitors | 11 | 2015 | 589 | 0.580 |
Why?
|
| MART-1 Antigen | 5 | 2014 | 19 | 0.530 |
Why?
|
| Lymphocytes | 4 | 2014 | 464 | 0.520 |
Why?
|
| Hematologic Neoplasms | 1 | 2019 | 329 | 0.520 |
Why?
|
| Adoptive Transfer | 3 | 2012 | 168 | 0.490 |
Why?
|
| Antineoplastic Agents | 13 | 2017 | 2360 | 0.490 |
Why?
|
| CD4-Positive T-Lymphocytes | 6 | 2019 | 425 | 0.490 |
Why?
|
| Immunotherapy | 8 | 2019 | 629 | 0.480 |
Why?
|
| Mice | 28 | 2022 | 11356 | 0.450 |
Why?
|
| Carbonic Anhydrases | 1 | 2013 | 15 | 0.450 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 5 | 2021 | 123 | 0.440 |
Why?
|
| Tumor Microenvironment | 6 | 2022 | 418 | 0.440 |
Why?
|
| Antibodies, Monoclonal | 8 | 2015 | 1376 | 0.430 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 5 | 2007 | 112 | 0.420 |
Why?
|
| Genetic Engineering | 3 | 2011 | 114 | 0.410 |
Why?
|
| Cell Differentiation | 4 | 2021 | 1458 | 0.410 |
Why?
|
| Gelsolin | 5 | 2005 | 11 | 0.400 |
Why?
|
| Antigens, CD | 7 | 2011 | 458 | 0.400 |
Why?
|
| HLA-A2 Antigen | 2 | 2010 | 31 | 0.390 |
Why?
|
| Lymphocyte Activation | 11 | 2022 | 728 | 0.370 |
Why?
|
| Ovarian Neoplasms | 3 | 2022 | 744 | 0.370 |
Why?
|
| Animals | 33 | 2022 | 26590 | 0.370 |
Why?
|
| Flow Cytometry | 10 | 2012 | 679 | 0.360 |
Why?
|
| Protein Engineering | 1 | 2010 | 140 | 0.340 |
Why?
|
| Cytotoxicity, Immunologic | 5 | 2010 | 213 | 0.330 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2013 | 426 | 0.330 |
Why?
|
| Humans | 64 | 2023 | 86678 | 0.320 |
Why?
|
| Mice, Inbred C57BL | 12 | 2019 | 3095 | 0.320 |
Why?
|
| Gene Transfer Techniques | 2 | 2010 | 152 | 0.310 |
Why?
|
| Disease Models, Animal | 3 | 2014 | 2231 | 0.310 |
Why?
|
| Immune Tolerance | 1 | 2010 | 337 | 0.300 |
Why?
|
| Kidney Neoplasms | 1 | 2013 | 621 | 0.300 |
Why?
|
| Mice, Transgenic | 7 | 2021 | 1540 | 0.280 |
Why?
|
| Cell- and Tissue-Based Therapy | 2 | 2023 | 49 | 0.280 |
Why?
|
| Neoplasm Proteins | 6 | 2010 | 532 | 0.280 |
Why?
|
| Bone Marrow Cells | 1 | 2007 | 253 | 0.270 |
Why?
|
| T-Lymphocytes, Cytotoxic | 4 | 2014 | 315 | 0.270 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2008 | 189 | 0.260 |
Why?
|
| Receptor, Macrophage Colony-Stimulating Factor | 2 | 2015 | 9 | 0.250 |
Why?
|
| Epitopes | 3 | 2010 | 255 | 0.250 |
Why?
|
| Prostatic Neoplasms | 2 | 2021 | 1721 | 0.250 |
Why?
|
| Leukemia, Myeloid | 2 | 2003 | 249 | 0.250 |
Why?
|
| CD40 Ligand | 2 | 2003 | 69 | 0.240 |
Why?
|
| Signal Transduction | 8 | 2022 | 3243 | 0.240 |
Why?
|
| Monitoring, Immunologic | 2 | 2021 | 17 | 0.230 |
Why?
|
| Tumor Cells, Cultured | 4 | 2012 | 1041 | 0.230 |
Why?
|
| B7-1 Antigen | 2 | 2003 | 75 | 0.230 |
Why?
|
| Mitochondria | 3 | 2005 | 535 | 0.230 |
Why?
|
| Mice, SCID | 5 | 2021 | 252 | 0.230 |
Why?
|
| Apoptosis | 7 | 2014 | 1683 | 0.230 |
Why?
|
| Membrane Potentials | 2 | 2005 | 435 | 0.220 |
Why?
|
| Cell Survival | 9 | 2021 | 969 | 0.220 |
Why?
|
| Hematopoietic Stem Cells | 3 | 2014 | 292 | 0.220 |
Why?
|
| CTLA-4 Antigen | 5 | 2015 | 135 | 0.220 |
Why?
|
| Adenocarcinoma | 1 | 2010 | 1169 | 0.220 |
Why?
|
| T Cell Transcription Factor 1 | 1 | 2022 | 23 | 0.210 |
Why?
|
| MAP Kinase Signaling System | 5 | 2017 | 192 | 0.210 |
Why?
|
| Receptors, CXCR6 | 1 | 2021 | 5 | 0.210 |
Why?
|
| Interferon Type I | 1 | 2022 | 175 | 0.200 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2022 | 54 | 0.200 |
Why?
|
| Mitochondria, Liver | 2 | 2000 | 27 | 0.200 |
Why?
|
| Genes, ras | 2 | 2012 | 96 | 0.200 |
Why?
|
| Cytochrome c Group | 2 | 2000 | 82 | 0.200 |
Why?
|
| Porphyrins | 1 | 2021 | 39 | 0.200 |
Why?
|
| Female | 25 | 2022 | 44550 | 0.200 |
Why?
|
| Myofibroblasts | 1 | 2021 | 43 | 0.190 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2021 | 90 | 0.190 |
Why?
|
| Photosensitizing Agents | 1 | 2021 | 48 | 0.190 |
Why?
|
| Quinoxalines | 1 | 2021 | 50 | 0.190 |
Why?
|
| Models, Animal | 2 | 2012 | 263 | 0.190 |
Why?
|
| Intracellular Membranes | 1 | 2000 | 117 | 0.180 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2021 | 154 | 0.180 |
Why?
|
| Cytokines | 5 | 2019 | 778 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-akt | 4 | 2013 | 322 | 0.180 |
Why?
|
| Genes, T-Cell Receptor | 1 | 2019 | 10 | 0.170 |
Why?
|
| Wound Healing | 1 | 2021 | 344 | 0.170 |
Why?
|
| Gene Library | 2 | 2018 | 130 | 0.170 |
Why?
|
| Single-Cell Analysis | 2 | 2017 | 134 | 0.170 |
Why?
|
| Repressor Proteins | 2 | 2021 | 403 | 0.160 |
Why?
|
| Cell Engineering | 1 | 2018 | 5 | 0.160 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2010 | 376 | 0.160 |
Why?
|
| Immunity | 1 | 2019 | 136 | 0.160 |
Why?
|
| Male | 22 | 2021 | 40988 | 0.160 |
Why?
|
| Vancomycin | 1 | 1998 | 72 | 0.160 |
Why?
|
| Gene Expression | 3 | 2013 | 1284 | 0.150 |
Why?
|
| Gene Expression Profiling | 2 | 2021 | 1384 | 0.150 |
Why?
|
| Immunotherapy, Active | 2 | 2015 | 15 | 0.150 |
Why?
|
| Neutropenia | 1 | 1998 | 215 | 0.150 |
Why?
|
| Neutrophils | 1 | 2019 | 307 | 0.150 |
Why?
|
| Fever | 1 | 1998 | 125 | 0.150 |
Why?
|
| Cell Proliferation | 6 | 2019 | 1579 | 0.150 |
Why?
|
| Mutation | 7 | 2015 | 3968 | 0.150 |
Why?
|
| Interleukin-4 | 3 | 2007 | 127 | 0.150 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2019 | 272 | 0.150 |
Why?
|
| Pyrimidinones | 2 | 2015 | 36 | 0.140 |
Why?
|
| Pyridones | 2 | 2015 | 51 | 0.140 |
Why?
|
| Cell Culture Techniques | 2 | 2021 | 188 | 0.140 |
Why?
|
| Neoplasm Transplantation | 5 | 2021 | 391 | 0.140 |
Why?
|
| Monocytes | 2 | 2009 | 216 | 0.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2021 | 1197 | 0.130 |
Why?
|
| MAP Kinase Kinase 1 | 2 | 2012 | 36 | 0.130 |
Why?
|
| Tissue Distribution | 2 | 2019 | 290 | 0.130 |
Why?
|
| Positron-Emission Tomography | 2 | 2014 | 329 | 0.130 |
Why?
|
| fas Receptor | 3 | 2011 | 75 | 0.130 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2015 | 41 | 0.130 |
Why?
|
| Membrane Proteins | 3 | 2014 | 1196 | 0.130 |
Why?
|
| Coculture Techniques | 3 | 2021 | 164 | 0.130 |
Why?
|
| Genes, Transgenic, Suicide | 1 | 2014 | 3 | 0.130 |
Why?
|
| Cloning, Molecular | 5 | 2018 | 646 | 0.130 |
Why?
|
| Antibodies, Blocking | 2 | 2011 | 21 | 0.120 |
Why?
|
| Histocompatibility Antigens Class I | 3 | 2011 | 203 | 0.120 |
Why?
|
| Cell Cycle | 5 | 2015 | 502 | 0.120 |
Why?
|
| Adjuvants, Immunologic | 2 | 2006 | 167 | 0.120 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2014 | 85 | 0.120 |
Why?
|
| Kinetics | 2 | 2010 | 1513 | 0.110 |
Why?
|
| Natural Killer T-Cells | 1 | 2013 | 39 | 0.110 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily A | 1 | 2013 | 3 | 0.110 |
Why?
|
| Carbonic Anhydrase IX | 1 | 2013 | 11 | 0.110 |
Why?
|
| Chemokine CCL1 | 1 | 2013 | 4 | 0.110 |
Why?
|
| Fibrinogen | 1 | 2013 | 56 | 0.110 |
Why?
|
| Mice, Inbred BALB C | 2 | 2013 | 1047 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 1 | 1998 | 747 | 0.110 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2013 | 222 | 0.110 |
Why?
|
| Lectins, C-Type | 1 | 2013 | 85 | 0.110 |
Why?
|
| Jurkat Cells | 4 | 2018 | 77 | 0.110 |
Why?
|
| Cell Separation | 2 | 2010 | 196 | 0.110 |
Why?
|
| Uveal Neoplasms | 1 | 2012 | 11 | 0.110 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2013 | 458 | 0.110 |
Why?
|
| Cell Adhesion Molecules | 1 | 2013 | 163 | 0.110 |
Why?
|
| Combined Modality Therapy | 2 | 2015 | 1686 | 0.110 |
Why?
|
| Congresses as Topic | 1 | 2012 | 116 | 0.100 |
Why?
|
| Fas Ligand Protein | 1 | 2011 | 49 | 0.100 |
Why?
|
| Th1 Cells | 2 | 2013 | 164 | 0.100 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 2 | 2010 | 132 | 0.100 |
Why?
|
| Adult | 14 | 2014 | 25659 | 0.100 |
Why?
|
| Herpesvirus 1, Human | 1 | 2014 | 244 | 0.100 |
Why?
|
| Gene Amplification | 1 | 2012 | 131 | 0.100 |
Why?
|
| Cell Line | 5 | 2012 | 2469 | 0.100 |
Why?
|
| Models, Biological | 1 | 2019 | 1749 | 0.100 |
Why?
|
| Receptors, Cell Surface | 1 | 2013 | 286 | 0.100 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2013 | 295 | 0.100 |
Why?
|
| Recombinant Proteins | 3 | 2003 | 1015 | 0.100 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2011 | 23 | 0.100 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 1998 | 878 | 0.100 |
Why?
|
| Azacitidine | 1 | 2011 | 137 | 0.100 |
Why?
|
| Ribonucleoside Diphosphate Reductase | 1 | 2010 | 6 | 0.100 |
Why?
|
| HLA-A Antigens | 1 | 2010 | 44 | 0.100 |
Why?
|
| Antineoplastic Protocols | 1 | 2010 | 9 | 0.100 |
Why?
|
| Antibodies | 1 | 2013 | 350 | 0.100 |
Why?
|
| Monophenol Monooxygenase | 1 | 2010 | 9 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 15 | 2 | 2002 | 63 | 0.100 |
Why?
|
| Tumor Escape | 1 | 2010 | 49 | 0.090 |
Why?
|
| Neoplasms, Experimental | 1 | 2012 | 269 | 0.090 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2010 | 38 | 0.090 |
Why?
|
| Survival Analysis | 2 | 2021 | 1538 | 0.090 |
Why?
|
| Aged | 11 | 2019 | 18423 | 0.090 |
Why?
|
| Transforming Growth Factor beta | 1 | 2012 | 301 | 0.090 |
Why?
|
| Dacarbazine | 1 | 2010 | 102 | 0.090 |
Why?
|
| Gene Silencing | 1 | 2010 | 172 | 0.090 |
Why?
|
| Peptide Fragments | 2 | 2014 | 460 | 0.090 |
Why?
|
| Molecular Imaging | 1 | 2010 | 64 | 0.090 |
Why?
|
| Oximes | 3 | 2015 | 14 | 0.090 |
Why?
|
| Genes, Reporter | 1 | 2010 | 268 | 0.090 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2010 | 153 | 0.090 |
Why?
|
| Histocompatibility Antigens | 1 | 2009 | 35 | 0.090 |
Why?
|
| Cytological Techniques | 1 | 2009 | 30 | 0.090 |
Why?
|
| Protein Array Analysis | 1 | 2009 | 50 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2014 | 930 | 0.090 |
Why?
|
| Neoplasm Metastasis | 5 | 2014 | 1056 | 0.090 |
Why?
|
| Transfection | 3 | 2007 | 896 | 0.090 |
Why?
|
| Glioma | 1 | 2011 | 285 | 0.090 |
Why?
|
| Middle Aged | 12 | 2014 | 25040 | 0.080 |
Why?
|
| Caspases | 2 | 2000 | 155 | 0.080 |
Why?
|
| DNA, Single-Stranded | 1 | 2009 | 92 | 0.080 |
Why?
|
| Nitrophenols | 1 | 2008 | 11 | 0.080 |
Why?
|
| RNA, Small Interfering | 1 | 2010 | 547 | 0.080 |
Why?
|
| DNA, Complementary | 4 | 2009 | 393 | 0.080 |
Why?
|
| Imidazoles | 3 | 2015 | 162 | 0.080 |
Why?
|
| Hepacivirus | 1 | 2009 | 160 | 0.080 |
Why?
|
| Biphenyl Compounds | 1 | 2008 | 68 | 0.080 |
Why?
|
| Immunophenotyping | 2 | 2010 | 211 | 0.080 |
Why?
|
| MicroRNAs | 1 | 2013 | 534 | 0.080 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2014 | 196 | 0.080 |
Why?
|
| Cells, Cultured | 4 | 2018 | 2819 | 0.080 |
Why?
|
| Cytomegalovirus | 1 | 2007 | 76 | 0.070 |
Why?
|
| Luciferases | 1 | 2007 | 118 | 0.070 |
Why?
|
| Phosphatidylinositol 3-Kinases | 3 | 2013 | 262 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 3 | 2015 | 266 | 0.070 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2007 | 158 | 0.070 |
Why?
|
| HEK293 Cells | 3 | 2013 | 615 | 0.070 |
Why?
|
| Mice, Inbred NOD | 2 | 2018 | 187 | 0.070 |
Why?
|
| Aminoquinolines | 1 | 2006 | 17 | 0.070 |
Why?
|
| Immunohistochemistry | 2 | 2007 | 1753 | 0.070 |
Why?
|
| Carrier Proteins | 2 | 1999 | 673 | 0.060 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2006 | 81 | 0.060 |
Why?
|
| Phenotype | 4 | 2017 | 2380 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 2438 | 0.060 |
Why?
|
| Retroviridae | 2 | 2018 | 79 | 0.060 |
Why?
|
| Proteome | 2 | 2017 | 124 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 928 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2012 | 1077 | 0.060 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2004 | 23 | 0.060 |
Why?
|
| Transgenes | 3 | 2011 | 180 | 0.060 |
Why?
|
| RNA, Messenger | 2 | 2022 | 1981 | 0.060 |
Why?
|
| Base Sequence | 4 | 2012 | 2330 | 0.060 |
Why?
|
| Colonic Neoplasms | 1 | 2008 | 558 | 0.060 |
Why?
|
| Aged, 80 and over | 5 | 2013 | 6513 | 0.060 |
Why?
|
| Amyloid beta-Peptides | 1 | 2005 | 203 | 0.060 |
Why?
|
| Promoter Regions, Genetic | 1 | 2007 | 937 | 0.060 |
Why?
|
| Neoplasm Staging | 3 | 2014 | 1939 | 0.060 |
Why?
|
| Drug Synergism | 2 | 2015 | 303 | 0.060 |
Why?
|
| Interleukin-12 | 1 | 2003 | 108 | 0.060 |
Why?
|
| Caspase 3 | 2 | 2000 | 159 | 0.060 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 2002 | 74 | 0.060 |
Why?
|
| Antigens, CD34 | 2 | 2014 | 158 | 0.050 |
Why?
|
| Immunity, Cellular | 2 | 2013 | 177 | 0.050 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 2 | 2013 | 28 | 0.050 |
Why?
|
| eIF-2 Kinase | 1 | 2022 | 46 | 0.050 |
Why?
|
| Lymphocyte Count | 2 | 2014 | 94 | 0.050 |
Why?
|
| Unfolded Protein Response | 1 | 2022 | 39 | 0.050 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2015 | 78 | 0.050 |
Why?
|
| NAD | 1 | 2022 | 65 | 0.050 |
Why?
|
| Analysis of Variance | 1 | 2004 | 912 | 0.050 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2022 | 83 | 0.050 |
Why?
|
| Granzymes | 1 | 2022 | 93 | 0.050 |
Why?
|
| Gene Expression Regulation | 1 | 2010 | 1921 | 0.050 |
Why?
|
| Treatment Outcome | 4 | 2014 | 7998 | 0.050 |
Why?
|
| Tryptophan | 1 | 2022 | 90 | 0.050 |
Why?
|
| Testis | 1 | 2002 | 152 | 0.050 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2012 | 64 | 0.050 |
Why?
|
| Survival Rate | 2 | 2021 | 1864 | 0.050 |
Why?
|
| NF-kappa B | 2 | 2017 | 445 | 0.050 |
Why?
|
| Alzheimer Disease | 1 | 2005 | 470 | 0.050 |
Why?
|
| Biophysics | 1 | 2021 | 152 | 0.050 |
Why?
|
| Stereoisomerism | 1 | 2021 | 102 | 0.050 |
Why?
|
| Cell Division | 1 | 2002 | 696 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 2 | 2012 | 101 | 0.050 |
Why?
|
| Porins | 1 | 2000 | 21 | 0.050 |
Why?
|
| Atractyloside | 1 | 2000 | 2 | 0.050 |
Why?
|
| Ion Transport | 1 | 2000 | 81 | 0.050 |
Why?
|
| Rats | 3 | 2005 | 3992 | 0.050 |
Why?
|
| Protoporphyrins | 1 | 2000 | 19 | 0.050 |
Why?
|
| Phosphatidylinositols | 1 | 2000 | 21 | 0.050 |
Why?
|
| Caspase 8 | 1 | 2000 | 34 | 0.050 |
Why?
|
| Thapsigargin | 1 | 2000 | 55 | 0.050 |
Why?
|
| Acute Disease | 1 | 2002 | 826 | 0.050 |
Why?
|
| Caspase 9 | 1 | 2000 | 48 | 0.050 |
Why?
|
| Aging | 1 | 2005 | 691 | 0.050 |
Why?
|
| Staurosporine | 1 | 2000 | 33 | 0.050 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2000 | 47 | 0.050 |
Why?
|
| Photochemotherapy | 1 | 2021 | 97 | 0.050 |
Why?
|
| Methylation | 1 | 2021 | 251 | 0.050 |
Why?
|
| Macrophages | 2 | 2015 | 557 | 0.050 |
Why?
|
| Structure-Activity Relationship | 1 | 2021 | 408 | 0.050 |
Why?
|
| Extracellular Matrix | 1 | 2021 | 232 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 2 | 2014 | 853 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2021 | 217 | 0.040 |
Why?
|
| Granulocytes | 1 | 2019 | 37 | 0.040 |
Why?
|
| Muromonab-CD3 | 1 | 2019 | 69 | 0.040 |
Why?
|
| Vaccination | 2 | 2014 | 254 | 0.040 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2019 | 17 | 0.040 |
Why?
|
| Complement C3 | 1 | 2019 | 58 | 0.040 |
Why?
|
| CD28 Antigens | 1 | 2019 | 88 | 0.040 |
Why?
|
| Histones | 1 | 2021 | 311 | 0.040 |
Why?
|
| Up-Regulation | 2 | 2011 | 715 | 0.040 |
Why?
|
| Drug Resistance, Microbial | 1 | 1998 | 72 | 0.040 |
Why?
|
| Cysteine Endopeptidases | 1 | 1998 | 87 | 0.040 |
Why?
|
| Smoking | 1 | 2002 | 609 | 0.040 |
Why?
|
| Frozen Sections | 1 | 2018 | 48 | 0.040 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 1998 | 47 | 0.040 |
Why?
|
| Markov Chains | 1 | 2017 | 125 | 0.040 |
Why?
|
| Transplantation, Autologous | 1 | 1998 | 331 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2021 | 1924 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2021 | 481 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2000 | 645 | 0.040 |
Why?
|
| Neurons | 1 | 2005 | 1547 | 0.040 |
Why?
|
| DNA Methylation | 1 | 2021 | 628 | 0.030 |
Why?
|
| Blotting, Western | 2 | 2012 | 782 | 0.030 |
Why?
|
| Proteomics | 1 | 2017 | 211 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 1998 | 455 | 0.030 |
Why?
|
| Membrane Glycoproteins | 2 | 2009 | 428 | 0.030 |
Why?
|
| Adaptation, Physiological | 1 | 2017 | 306 | 0.030 |
Why?
|
| Aminopyridines | 1 | 2015 | 38 | 0.030 |
Why?
|
| Major Histocompatibility Complex | 1 | 2015 | 81 | 0.030 |
Why?
|
| Complementarity Determining Regions | 1 | 2014 | 24 | 0.030 |
Why?
|
| Substrate Specificity | 2 | 2009 | 347 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2010 | 1961 | 0.030 |
Why?
|
| Pyrroles | 1 | 2015 | 184 | 0.030 |
Why?
|
| Hydroxamic Acids | 1 | 2014 | 49 | 0.030 |
Why?
|
| Clonal Evolution | 1 | 2013 | 15 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2015 | 159 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2014 | 100 | 0.030 |
Why?
|
| Head and Neck Neoplasms | 1 | 2021 | 1052 | 0.030 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2013 | 15 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2008 | 557 | 0.030 |
Why?
|
| Receptors, CCR2 | 1 | 2013 | 35 | 0.030 |
Why?
|
| Prognosis | 1 | 2021 | 3680 | 0.030 |
Why?
|
| Chemokine CCL2 | 1 | 2013 | 47 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2014 | 369 | 0.030 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2013 | 128 | 0.030 |
Why?
|
| ras Proteins | 1 | 2013 | 128 | 0.030 |
Why?
|
| Th2 Cells | 1 | 2013 | 146 | 0.030 |
Why?
|
| Phosphoproteins | 1 | 2014 | 255 | 0.030 |
Why?
|
| Radioactive Tracers | 1 | 2012 | 6 | 0.030 |
Why?
|
| DNA Damage | 1 | 2014 | 366 | 0.030 |
Why?
|
| Microchip Analytical Procedures | 1 | 2011 | 3 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 115 | 0.030 |
Why?
|
| Exome | 1 | 2012 | 127 | 0.020 |
Why?
|
| Stem Cell Transplantation | 1 | 2012 | 183 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2013 | 276 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2013 | 506 | 0.020 |
Why?
|
| Neoplastic Stem Cells | 1 | 2012 | 143 | 0.020 |
Why?
|
| K562 Cells | 1 | 2010 | 43 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2012 | 171 | 0.020 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 1 | 2010 | 18 | 0.020 |
Why?
|
| Osmolar Concentration | 1 | 2010 | 181 | 0.020 |
Why?
|
| Benzimidazoles | 1 | 2012 | 140 | 0.020 |
Why?
|
| Thymus Gland | 1 | 2011 | 195 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2010 | 104 | 0.020 |
Why?
|
| S Phase | 1 | 2010 | 62 | 0.020 |
Why?
|
| Cell Death | 1 | 2011 | 256 | 0.020 |
Why?
|
| G1 Phase | 1 | 2010 | 63 | 0.020 |
Why?
|
| Computational Biology | 1 | 2014 | 528 | 0.020 |
Why?
|
| Precision Medicine | 1 | 2015 | 395 | 0.020 |
Why?
|
| Exons | 1 | 2012 | 450 | 0.020 |
Why?
|
| Viral Structural Proteins | 1 | 2009 | 19 | 0.020 |
Why?
|
| B7-2 Antigen | 1 | 2009 | 40 | 0.020 |
Why?
|
| Cell Communication | 1 | 2010 | 194 | 0.020 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2010 | 138 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2011 | 286 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2010 | 199 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2002 | 879 | 0.020 |
Why?
|
| Glass | 1 | 2009 | 15 | 0.020 |
Why?
|
| Streptavidin | 1 | 2009 | 14 | 0.020 |
Why?
|
| DNA Restriction Enzymes | 1 | 2009 | 98 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2002 | 2262 | 0.020 |
Why?
|
| Immobilized Proteins | 1 | 2009 | 14 | 0.020 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2009 | 37 | 0.020 |
Why?
|
| DNA Primers | 2 | 2002 | 543 | 0.020 |
Why?
|
| Intracellular Space | 1 | 2009 | 38 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2009 | 245 | 0.020 |
Why?
|
| Protein Structure, Quaternary | 1 | 2009 | 99 | 0.020 |
Why?
|
| Stem Cells | 1 | 2011 | 351 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2010 | 692 | 0.020 |
Why?
|
| Immunoglobulins | 1 | 2009 | 148 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2010 | 339 | 0.020 |
Why?
|
| Receptors, Death Domain | 1 | 2008 | 3 | 0.020 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2008 | 10 | 0.020 |
Why?
|
| Killer Cells, Lymphokine-Activated | 1 | 2008 | 27 | 0.020 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2008 | 25 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2010 | 989 | 0.020 |
Why?
|
| Interleukin-17 | 1 | 2009 | 101 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 689 | 0.020 |
Why?
|
| Protein Multimerization | 1 | 2009 | 173 | 0.020 |
Why?
|
| Young Adult | 2 | 2010 | 5980 | 0.020 |
Why?
|
| Listeria monocytogenes | 1 | 2008 | 89 | 0.020 |
Why?
|
| Autoimmunity | 1 | 2009 | 160 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 2 | 1999 | 176 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2010 | 1106 | 0.020 |
Why?
|
| Chromosome Mapping | 2 | 2002 | 1074 | 0.020 |
Why?
|
| Biopsy | 1 | 2011 | 1163 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2012 | 1169 | 0.020 |
Why?
|
| Virus Internalization | 1 | 2007 | 39 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2014 | 1351 | 0.020 |
Why?
|
| Protein Binding | 1 | 2010 | 1457 | 0.020 |
Why?
|
| Piperazines | 1 | 2008 | 272 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2011 | 926 | 0.020 |
Why?
|
| gp100 Melanoma Antigen | 1 | 2006 | 12 | 0.020 |
Why?
|
| Calcium | 2 | 2001 | 1156 | 0.020 |
Why?
|
| Spleen | 1 | 2007 | 430 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2010 | 469 | 0.020 |
Why?
|
| Brain Neoplasms | 1 | 2011 | 763 | 0.020 |
Why?
|
| Neurotoxins | 1 | 2005 | 49 | 0.020 |
Why?
|
| PC12 Cells | 1 | 2005 | 115 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2007 | 790 | 0.020 |
Why?
|
| Genome, Human | 1 | 2010 | 756 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2008 | 683 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 1998 | 8496 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2012 | 1464 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 2601 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2003 | 224 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2009 | 2706 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 1992 | 0.010 |
Why?
|
| Liver | 1 | 2007 | 1230 | 0.010 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2001 | 27 | 0.010 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2006 | 579 | 0.010 |
Why?
|
| Histidine | 1 | 2001 | 55 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2002 | 258 | 0.010 |
Why?
|
| Voltage-Dependent Anion Channels | 1 | 2000 | 3 | 0.010 |
Why?
|
| bcl-X Protein | 1 | 2000 | 52 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 2000 | 94 | 0.010 |
Why?
|
| Liposomes | 1 | 2000 | 91 | 0.010 |
Why?
|
| Chelating Agents | 1 | 2000 | 69 | 0.010 |
Why?
|
| HeLa Cells | 1 | 2000 | 498 | 0.010 |
Why?
|
| HL-60 Cells | 1 | 1999 | 20 | 0.010 |
Why?
|
| Species Specificity | 1 | 2000 | 678 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1999 | 256 | 0.010 |
Why?
|
| Open Reading Frames | 1 | 1999 | 117 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2000 | 736 | 0.010 |
Why?
|
| Hydrolysis | 1 | 1998 | 141 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 1999 | 348 | 0.010 |
Why?
|
| Cell Movement | 1 | 2001 | 758 | 0.010 |
Why?
|
| Actins | 1 | 2000 | 451 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 1999 | 378 | 0.010 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1998 | 434 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 1999 | 1135 | 0.010 |
Why?
|
| Time Factors | 1 | 2001 | 5214 | 0.010 |
Why?
|